Compare 10X Genomics Inc (TXG) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs State Street SPDR S&P Homebuilders ETF — how do they compare? 10X Genomics Inc trades at $67.8 (market cap $8.55B), while State Street SPDR S&P Homebuilders ETF trades at $99.14. The key difference: 10X Genomics Inc is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals.
| TXG | XHB | |
|---|---|---|
Market Cap | $8.55B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $67.29 | $121.36 |
52-Week Low | $11.34 | $94.86 |
Enterprise Value | $8.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
XHB trades at $100.75, down 2.42% today amid bearish technical signals. The ETF shows neutral oscillators but bearish moving averages, with support at $98-$100 and resistance at $102-$105. Recent housing data shows mixed signals with new home sales rising 1.6% in June (Census Bureau, June 2026) while existing home sales declined 2.4% (WSJ, July 9, 2026).
The homebuilding sector faces headwinds from high mortgage rates and record home prices, though institutional interest remains with Greenland Capital's $17.33 million investment (Defense World, September 7, 2026). Key catalysts include housing affordability legislation and potential market rebound opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
